Brief: MaxCyte Posts H1 Revenue Of $6.9 Mln
July 16 (Reuters) - MaxCyte Inc MXCT.L :
* REVENUES FOR FIRST HALF OF 2018 WERE $6.9 MILLION, UP
APPROXIMATELY 11.6% (H1 2017: $6.2 MILLION)
* BOARD ANTICIPATES CONTINUED PROGRESS FOR REMAINDER OF 2018
FINANCIAL YEAR AND COMPANY IS TRADING IN LINE WITH EXPECTATIONS
Source text for Eikon: ID:nRSP6675Ua
Further company coverage: MXCT.L
(Reuters.Briefs@thomsonreuters.com)
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics